title: Effects of interleukin-2 and interferon-beta treatment on lymphocytes in various tumor-bearing mice.
abstract: Treatment with a combination of recombinant human interleukin-2 (rHIL-2) and recombinant mouse interferon-beta (rIFN-beta) had a significant antitumor effect against subcutaneous (s.c.) adenocarcinoma-755 and colon-38, but this combination performed no better than rHIL-2 alone against s.c. Lewis lung carcinoma in C57BL/6 mice. Injecting a combination of rHIL-2 and rIFN-beta into mice with adenocarcinoma-755 or colon-38 tumors resulted in a marked increase in L3T4+, Lyt-2+ and asialo GM1+ cells in the peritoneal cavity. On the other hand, the treatment of mice with Lewis lung carcinoma with rHIL-2 and rIFN-beta produced almost no change of each subset in the peritoneal cavity compared to cytokine alone. Thus, sensitive tumors (adenocarcinoma-755 and colon-38) in combined treatment with rHIL-2 and rIFN-beta markedly increased L3T4+, Lyt-2+ and asialo GM1+ cells in the peritoneal cavity, but the insensitive tumor (Lewis lung carcinoma) did not.
authors.affiliation: Chemotherapy Division, National Cancer Center Research Institute, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Iigo
authors.forename: K
authors.initials: K
authors.lastname: Nishikata
authors.forename: Y
authors.initials: Y
authors.lastname: Nakajima
authors.forename: M
authors.initials: M
authors.lastname: Moriyama
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D003110:Colonic Neoplasms / Q000188:drug therapy; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007370:Interferon Type I / Q000008:administration & dosage / Q000494:pharmacology*; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta; D007371:Interferon-gamma / Q000008:administration & dosage; D007376:Interleukin-2 / Q000494:pharmacology*; D008175:Lung Neoplasms / Q000188:drug therapy; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000628:therapy*; D010529:Peritoneal Cavity; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D007371:Interferon-gamma; D000068556:Interferon beta-1a